These indicators depend heavily on primary tumour samples, are often expensive, strenuous and taking a lot of time and are usually limited their use in clinical practice.19 To a greater extent, it is complicated when some variable factors are taken into consideration such as ER status, PR status, Ki‐67 status, HER2 status of breast carcinoma or post‐operative adjuvant treatment. The gene discussed is ERBB2; the disease is breast carcinoma.